Key Documents

View All Documentation

244279

Hydrofluoric acid

Name: Hydrofluoric acid
Brand: SIAL

ACS reagent, 48%

Synonym(s):

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

CAS Number:

7664-39-3

Molecular Weight:

20.01

UNSPSC Code:

12352106

PubChem Substance ID:

24854662

MDL number:

MFCD00011346

Assay:

48%, 48.0-51.0% (ACS specification)

Form:

liquid

Grade:

ACS reagent

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

ACS reagent

vapor density

1.27 (vs air)

vapor pressure

25 mmHg ( 20 °C)

assay

48%, 48.0-51.0% (ACS specification)

form

liquid

impurities

≤0.01% fluorosilicic acid

ign. residue

≤5 ppm

density

1.15 g/mL at 25 °C (lit.)

anion traces

SO₄^2- and SO₃^2-: ≤5 ppm, chloride (Cl^-): ≤5 ppm, phosphate (PO₄^3-): ≤1 ppm

cation traces

As: ≤0.005 ppm, Cu: ≤0.1 ppm, Fe: ≤1 ppm, heavy metals (as Pb): ≤0.5 ppm

SMILES string

[H+].[F-]

InChI

1S/FH/h1H

InChI key

KRHYYFGTRYWZRS-UHFFFAOYSA-N

Description

Other Notes

This product has been replaced by 695068-Sigma-Aldrich | Hydrofluoric acid, ACS reagent, 48% | HF

Still not finding the right product?

Explore all of our products under Hydrofluoric acid

pictograms

GHS06,GHS05

signalword

Danger

hcodes

H300 + H310 + H330,H314

pcodes

P260 - P270 - P280 - P303 + P361 + P353 - P304 + P340 + P310 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Eye Dam. 1 - Skin Corr. 1A

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.

Faiez Zannad et al.

European journal of heart failure, 17(7), 735-742 (2015-04-29)

Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after

Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model.

Ian Ford et al.

International journal of cardiology, 184, 163-169 (2015-02-24)

We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. We selected the

Paradoxical muscle sympathetic reflex activation in human heart failure.

Philip J Millar et al.

Circulation, 131(5), 459-468 (2014-12-04)

Muscle sympathetic activation in heart failure with reduced ejection fraction (HFrEF) has been attributed, on the basis of multiunit recordings, to attenuated inhibitory feedback from stretch-sensitive cardiopulmonary mechanoreceptors. However, such preparations integrate 2 populations of single units exhibiting directionally opposite

View All Related Papers